{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:10:32Z","timestamp":1792440632259,"version":"4.5.0"},"reference-count":79,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2026.2632657","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:10:15Z","timestamp":1772730615000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges"],"prefix":"10.1080","volume":"25","author":[{"given":"Joseph B.","family":"Domachowske","sequence":"first","affiliation":[{"name":"State University of New York","place":["Syracuse, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Zimet","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, and Zimet Research Consulting LLC","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hanage","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Sule","sequence":"additional","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahnuma","family":"Wahid","sequence":"additional","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Vicic","sequence":"additional","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00179-6"},{"key":"e_1_3_5_4_1","unstructured":"Sputnik V vaccine granted full permanent approval in Russia. 2022 [Press Release]."},{"key":"e_1_3_5_5_1","unstructured":"UK Medicines & Healthcare Products Regulatory Agency. ARCHIVE: conditions of authorisation for COVID-19 vaccine Pfizer\/BioNTech (Regulation 174). 2024."},{"key":"e_1_3_5_6_1","unstructured":"World Health Organization. COVID-19 advice for the public: getting vaccinated. 2022."},{"key":"e_1_3_5_7_1","unstructured":"U.S. Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19. 2025 [cited 2025 Feb 6]. Available from: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7240a3"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7205a1"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7331a1"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00114-7"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30264-3"},{"key":"e_1_3_5_13_1","unstructured":"Havers FP. COVID-19\u2013associated hospitalizations \u2014COVID-NET April 2025 update. Advisory Committee on Immunization Practices (ACIP) meeting. 2025 [2025 Apr 15]."},{"issue":"1","key":"e_1_3_5_14_1","first-page":"e53","article-title":"COVID-19 vaccines\u2019 protection over time and the need for booster doses; a systematic review","volume":"10","author":"Dadras O","year":"2022","unstructured":"Dadras O, SeyedAlinaghi S, Karimi A, et al. COVID-19 vaccines\u2019 protection over time and the need for booster doses; a systematic review. Arch Acad Emerg Med. 2022;10(1):e53.","journal-title":"Arch Acad Emerg Med"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1113793"},{"key":"e_1_3_5_16_1","unstructured":"U.S. Centers for Disease Control and Prevention. Vaccines for moderately to severely immunocompromised people. 2025. Available from: https:\/\/www.cdc.gov\/covid\/vaccines\/immunocompromised-people.html"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd22.240539"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd18.210123"},{"key":"e_1_3_5_19_1","unstructured":"World Health Organization. Ageing and health. 2025. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/15394492221134911"},{"key":"e_1_3_5_21_1","unstructured":"ModernaTX Inc. SPIKEVAX (COVID-19 Vaccine mRNA) injectable suspension for intramuscular use - 2024\u20132025 formula. Prescribing Information. 2025 [cited 2025 Aug]."},{"key":"e_1_3_5_22_1","unstructured":"Pfizer-BioNTech. COMIRNATY (COVID-19 Vaccine mRNA) suspension for injection for intramuscular use - 2024\u20132025 Formula. Prescribing Information. 2024 [cited 2025 Aug]."},{"key":"e_1_3_5_23_1","unstructured":"U.S. Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the NOVAVAX COVID-19 vaccine adjuvanted to prevent coronavirus disease 2019 (COVID-19). Revised 2024 Aug."},{"key":"e_1_3_5_24_1","unstructured":"Report from the International Coalition of Medicines Regulatory Authorities (ICMRA) and World Health Organization (WHO) workshop on global perspectives on COVID-19 vaccines strain update. Alignment on timing and data requirements. 2024 Feb 26\u201327. Available from: https:\/\/icmra.info\/drupal\/covid-19\/26_27february2024"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22759"},{"key":"e_1_3_5_26_1","unstructured":"Schnirring L. News brief: HHS awards $1.4 billion for project NextGen COVID countermeasures. 2023. Available from: https:\/\/www.cidrap.umn.edu\/business-preparedness\/hhs-awards-14-billion-project-nextgen-covid-countermeasures"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-00220-z"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.03.005"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.037"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf4100"},{"issue":"21","key":"e_1_3_5_31_1","first-page":"00356","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"0092","author":"McCallum M","year":"2021","unstructured":"McCallum M, De Marco A, Lempp FA, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;S0092-8674(21):00356\u201300351.","journal-title":"Cell"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2211153"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.06.005"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100204"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2400003"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1410"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106256"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v4i3.788"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2506929"},{"key":"e_1_3_5_42_1","article-title":"MNEXSPIKE (COVID-19 vaccine, mRNA) injectable suspension, for intramuscular use - 2024\u20132025 formula","author":"ModernaTX, Inc","year":"2025","unstructured":"ModernaTX, Inc. MNEXSPIKE (COVID-19 vaccine, mRNA) injectable suspension, for intramuscular use - 2024\u20132025 formula. Prescribing Information. 2025 [cited 2025 Aug].","journal-title":"Prescribing Information"},{"key":"e_1_3_5_43_1","unstructured":"U.S. Department of Health and Human Services. ACIP recommends COVID-19 immunization based on individual decision-making. 2025. Available from: https:\/\/www.hhs.gov\/press-room\/acip-recommends-covid19-vaccination-individual-decision-making.html"},{"key":"e_1_3_5_44_1","unstructured":"U.S. Centers for Disease Control and Prevention. CDC immunization schedule adopts individual-based decision-making for COVID-19 and standalone vaccination for chickenpox in toddlers. 2025. Available from: https:\/\/www.cdc.gov\/media\/releases\/2025\/cdc-immunization-schedule-adopts-individual-based-decision.html"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113017"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01091-1"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320434"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae695"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080848"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.11.023"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2190690"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf022"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00236-1"},{"key":"e_1_3_5_54_1","volume-title":"Presented at: ESCMID Global","author":"Chalkias S","year":"2025","unstructured":"Chalkias S, Grassi CM, Dennis P, et al. Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses. Presented at: ESCMID Global; Vienna, Austria; 2025 Apr 11\u201314."},{"key":"e_1_3_5_55_1","volume-title":"Presented at: Advisory Committee on Immunization Practices (ACIP) Meeting","author":"Rizkalla B","year":"2025","unstructured":"Rizkalla B. Overview of Moderna\u2019s investigational next generation COVID-19 vaccine, mRNA-1283, in individuals \u226512 years of age. Presented at: Advisory Committee on Immunization Practices (ACIP) Meeting; Atlanta, GA; 2025 Apr 15."},{"key":"e_1_3_5_56_1","volume-title":"Presented at: ESCMID Global","author":"Grassi CM","year":"2025","unstructured":"Grassi CM, Feng J, Wahid R, et al. Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged \u226512 years. Presented at: ESCMID Global; Vienna, Austria; 2025 Apr 11\u201314."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2549630"},{"key":"e_1_3_5_58_1","article-title":"Modeling the anticipated public health benefits of the next-generation COVID-19 mRNA-1283 vaccine: an interim U.S. population-level impact assessment","author":"Fust K","year":"2025","unstructured":"Fust K, Kohli M, Joshi K, et al. Modeling the anticipated public health benefits of the next-generation COVID-19 mRNA-1283 vaccine: an interim U.S. population-level impact assessment. medRxiv. 2025:2009.2026.25336704.","journal-title":"medRxiv"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2466726"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03173-6"},{"key":"e_1_3_5_61_1","volume-title":"Presented at: IDWeek","author":"Joshi K","year":"2025","unstructured":"Joshi K, Kohli M, Maschio M, et al. Potential impact of the next-generation COVID-19 mRNA-1283 vaccine on post-acute outcomes of COVID-19. Presented at: IDWeek; Atlanta, GA; 2025 Oct 19\u201322."},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.2024\/2004.2010.24305549"},{"key":"e_1_3_5_63_1","unstructured":"ClinicalTrials.gov. A study to evaluate the immunogenicity and safety of mRNA-1283 COVID-19 variant-containing formulations. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07089706"},{"key":"e_1_3_5_64_1","unstructured":"U.S. Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19. 2025 Feb 6 [accessed 2025 Mar]."},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.16.676634"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00589-9"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v2i2.85"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127947"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2437921"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2357230"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1011999"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.096"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1371380"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1627822"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2219185"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.2196\/56546"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127003"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072942"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2195786"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103428"},{"key":"e_1_3_5_81_1","unstructured":"ClinicalTrials.gov. A randomized trial evaluating a mRNA-VLP vaccine\u2019s immunogenicity and safety for COVID-19 (ARTEMIS-C). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06147063."}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2632657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:10:19Z","timestamp":1772730619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2026.2632657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2026.2632657"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2026.2632657","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2632657"}}